Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,451 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,225 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06250244 | 177Lu-LNC1011 in Patients with Metastatic Castration-resistant Prostate Cancer | unknown | Phase 1 / Phase 2 | 12 | Peking Union Medical College HospitalOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06505278 | The Impact of Medication Timing Adjustment on the Effect of Novel Hormonal Therapy | unknown | Phase 2 | 70 | Sun Yat-sen UniversityOTHER | 1 | Aug 5, 2024 | clinicaltrials |
| NCT03079323 |
| Trial to Investigate the Benefit of Elective Para-Aortic Radiotherapy (PART) for pN1 Prostate Cancer(PART) |
| unknown |
| Phase 2 |
| 137 |
| Universitaire Ziekenhuizen KU LeuvenOTHER |
| 1 |
| Jul 3, 2024 |
| clinicaltrials |
| NCT03080116 | Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy(ARNEO) | unknown | Phase 2 | 90 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06484361 | PET/MRI to Stage Prostate Cancer Patients | unknown | Phase 2 | 50 | IRCCS San RaffaeleOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT02042807 | To Evaluate the Effect of MCS® in Prostate Cancer Prevention(MCS-8) | unknown | Phase 2 | 702 | Health Ever Bio-Tech Co., Ltd.INDUSTRY | 1 | Jun 13, 2024 | clinicaltrials |
| NCT06227156 | Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer | unknown | Phase 2 | 40 | RemeGen Co., Ltd.INDUSTRY | 1 | May 23, 2024 | clinicaltrials |
| NCT03141671 | Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509) | unknown | Phase 2 | 345 | Dana-Farber Cancer InstituteOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT06081686 | Study of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate Cancer | unknown | Phase 1 / Phase 2 | 32 | Sinotau Pharmaceutical GroupINDUSTRY | 1 | May 3, 2024 | clinicaltrials |
| NCT05458544 | [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application(LUCIDA) | unknown | Phase 1 / Phase 2 | 26 | FutureChemINDUSTRY | 1 | Apr 29, 2024 | clinicaltrials |
| NCT05579184 | [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application_2(LUCIDA_2) | unknown | Phase 2 | 20 | FutureChemINDUSTRY | 1 | Apr 29, 2024 | clinicaltrials |
| NCT06385847 | To Assess The Patient Preference for Goserelin Microsphere Versus Goserelin Implant in Patients With Prostate Cancer | unknown | Phase 2 | 60 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Apr 26, 2024 | clinicaltrials |
| NCT03700099 | Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide | unknown | Phase 2 | 30 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT02266745 | A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts | unknown | Phase 2 | 109 | Promontory Therapeutics Inc.INDUSTRY | 2 | Apr 5, 2024 | clinicaltrials |
| NCT04903873 | A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 110 | EutilexINDUSTRY | 2 | Mar 15, 2024 | clinicaltrials |
| NCT04641078 | Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer(DART) | unknown | Phase 2 | 124 | University Hospital, GhentOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05627752 | Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage | unknown | Phase 2 / Phase 3 | 120 | Zhongnan HospitalOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT02077335 | Study of High-dose Rate (HDR) Monotherapy for Low and Intermediate Risk Prostate Cancer | unknown | Phase 2 | 50 | CSSS de GatineauOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT06251492 | Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID) | unknown | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03924466 | Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients(VUBAR) | unknown | Phase 2 | 55 | Universitair Ziekenhuis BrusselOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT03899077 | Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP(SAVE) | unknown | Phase 2 | 202 | Cancer Research AntwerpOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06221774 | Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors | unknown | Phase 1 / Phase 2 | 42 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT05150236 | EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC(ANZUP2001) | unknown | Phase 2 | 93 | Australian and New Zealand Urogenital and Prostate Cancer Trials GroupOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT06029036 | A Phase II Neoadjuvant Study of Darolutamide Plus ADT in Men With Localized Prostate Cancer | unknown | Phase 2 | 53 | Peking University First HospitalOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT02935205 | Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer | unknown | Phase 1 / Phase 2 | 38 | Mamta ParikhOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT04097002 | First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients. | unknown | Phase 1 / Phase 2 | 24 | Orca Therapeutics B.V.INDUSTRY | 1 | Oct 31, 2023 | clinicaltrials |
| NCT05555017 | Tracer-Guided Surgery for Recurrent Prostate Cancer(Trace-II) | unknown | Phase 2 | 60 | The Netherlands Cancer InstituteOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06006104 | Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer | unknown | Phase 1 / Phase 2 | 49 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | Aug 23, 2023 | clinicaltrials |
| NCT05900973 | A Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate Cancer | unknown | Phase 2 | 19 | D'Or Institute for Research and EducationOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT05955209 | Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC) | unknown | Phase 2 | 40 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jul 21, 2023 | clinicaltrials |
| NCT05841992 | Al18F-PSMA-617 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients | unknown | Phase 2 / Phase 3 | 100 | Peking Union Medical College HospitalOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT03774901 | Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma(PULSE) | unknown | Phase 2 | 32 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT03845751 | EvaluatioN of HIFU Hemiablation and Short Term AndrogeN Deprivation Therapy Combination to Enhance Prostate Cancer Control.(ENHANCE) | unknown | Phase 2 | 20 | Institut Mutualiste MontsourisOTHER | 1 | Jan 12, 2023 | clinicaltrials |
| NCT05249712 | Efficacy and Safety of Darolutamide Combined With ADT in High-risk/Very High-risk Localized Prostate Cancer | unknown | Phase 2 | 30 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jan 3, 2023 | clinicaltrials |
| NCT04356430 | Neoadjuvant Therapy of Abiraterone Plus ADT for High Risk Prostate Cancer | unknown | Phase 2 | 75 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Dec 16, 2022 | clinicaltrials |
| NCT05167175 | The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation | unknown | Phase 2 | 30 | Hongqian GuoOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT01197625 | Vaccine Therapy in Curative Resected Prostate Cancer Patients | unknown | Phase 1 / Phase 2 | 30 | Oslo University HospitalOTHER | 1 | Sep 27, 2022 | clinicaltrials |
| NCT05285319 | Trial Comparing Radical Radiotherapy to Prostate Only VS Prostate And Pelvic Lymph Nodes in Intermediate And High Risk Prostate Cancer | unknown | Phase 2 | 82 | Cairo UniversityOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT04796467 | 68Ga-P16-093 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients | unknown | Phase 2 / Phase 3 | 50 | Peking Union Medical College HospitalOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT04116775 | Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer. | unknown | Phase 2 | 32 | Julie Graff, MDFED | 1 | Jun 23, 2022 | clinicaltrials |
| NCT04300673 | Radio Guided Lymph Node Dissection in Oligometastatic Prostate Cancer Patients(DETECT) | unknown | Phase 1 / Phase 2 | 20 | Radboud University Medical CenterOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT04033432 | sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | unknown | Phase 2 | 14 | Northwestern UniversityOTHER | 1 | Apr 27, 2022 | clinicaltrials |
| NCT05327621 | Pamiparib in mCRPC With HRD or BRCA1/2 Mutation | unknown | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05286840 | 64Cu-SAR-bisPSMA Positron Emission Tomography of Patients With Known or Suspected Prostate Cancer | unknown | Phase 1 / Phase 2 | 150 | Luke Nordquist, MDOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT05212857 | Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer | unknown | Phase 2 | 160 | Fudan UniversityOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT05262608 | The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation(PROspect) | unknown | Phase 2 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT05156424 | A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer | unknown | Phase 1 / Phase 2 | 24 | Kira MurphyOTHER | 1 | Dec 14, 2021 | clinicaltrials |
| NCT04379362 | MRI-guided Focal Laser Ablation(Unicorn) | unknown | Phase 2 | 53 | Radboud University Medical CenterOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT03305224 | The Combination Therapy With Ra-223 and Enzalutamide(CORE-OCU) | unknown | Phase 2 | 10 | Taro Iguchi, MD, PHDOTHER | 1 | Sep 9, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Dec 11, 2024source: clinicaltrials